Biotech Genzyme Gets Favorable Pay Ruling.(B)(NASDAQ STOCKS IN THE NEWS)

Publication: Investor's Business Daily

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2005 Investor's Business Daily, Inc.

Byline: Marie Beerens

Genzyme broke out of a two-month double bottom early this month. The stock is nearly 4% above its 73.97 buy point.

The biotech specializes in treatments for rare genetic disorders, renal disease, orthopedics and organ transplants. The Centers for Medicare and Medicaid Services earlier this month...

Read the full article for free courtesy of your local library.